News Formal

Akero Therapeutics soars more than 100% in early trading on early 'fatty liver' trial data - San Francisco Business Times

  • 📰 SFBusinessTimes
  • ⏱ Reading Time:
  • 17 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 68%

United States News News

United States United States Latest News,United States United States Headlines

Results from a clinical trial of its drug in the 'fatty liver' disease NASH sent $AKRO's stock soaring

Encouraging data on a South San Francisco company's drug targeting the fatty liver disease NASH pushed its stock 120% higher in early trading Tuesday.

Most side effects — diarrhea, nausea, increased appetite and frequent bowel movements — were transient, the company said. EFX, formerly known as AKR-001, is Akero's lead product candidate, designed not only to reduce liver fat and inflammation but to reduce fibrosis. It is injected once a week into a layer of skin.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 78. in US

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Warriors, 49ers and Giants land on Forbes' 2022 most valuable teams list - San Francisco Business TimesThe NFL has made a run for the top spots this year, bumping the MLB and the NBA out of the top three.
Source: SFBusinessTimes - 🏆 78. / 68 Read more »

Universal Paragon Corp. proposes Project Axon at Sierra Point in Brisbane - San Francisco Business TimesThe proposed hotel near the Brisbane Marina is envisioned with over 600 rooms and an outdoor wedding chapel. An adjacent life sciences building will rise 11 stories.
Source: SFBusinessTimes - 🏆 78. / 68 Read more »